Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

被引：5

作者：

Goy, Andre ^{[1
]}

Jacobson, Caron A. ^{[2
]}

Flinn, Ian W. ^{[3
]}

Hill, Brian T. ^{[4
]}

Weng, Wen-Kai ^{[5
]}

Mountjoy, Luke ^{[6
]}

Olalekan, Oluwole ^{[7
]}

Zheng, Dan ^{[8
]}

Nunes, Ana ^{[8
]}

Zhang, Wangshu ^{[8
]}

Shen, Rhine R. ^{[8
]}

Kloos, Ioana ^{[8
]}

Wang, Michael L. ^{[9
]}

机构：

[1] John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[2] Dana Farber Canc Inst, Boston, MA USA

[3] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA

[4] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[5] Stanford Univ, Div Blood & Marrow Transplantat Cellular Therapy, Palo Alto, CA USA

[6] Colorado Blood Canc Inst, Denver, CO USA

[7] Vanderbilt Univ, Ctr Canc, Nashville, TN USA

[8] Gilead Co, Kite, Santa Monica, CA USA

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174273

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[1] Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis
Munoz, Javier
Reagan, Patrick M.
Goy, Andre
Miklos, David B.
Zheng, Dan
Fang, Xiang
Shen, Rhine R.
Siddiqi, Rubina
Kloos, Ioana
Kersten, Marie Jose
Wang, Michael
ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
[2] Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel ( Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2
Oluwole, Olalekan O.
Reagan, Patrick M.
Miklos, David B.
Locke, Frederick L.
Goy, Andre
Jacobson, Caron A.
Munoz, Javier L.
Forcade, Edouard
Topp, Max S.
Zheng, Dan
Nunes, Ana
Zhang, Wangshu
Shen, Rhine R.
Kloos, Ioana
Kersten, Marie Jose
Wang, Michael L.
BLOOD, 2023, 142
[3] Assessment of durable responses after brexucabtagene autoleucel (brexu-cel) in relapsed/refractory mantle cell lymphoma (R/R MCL)
Pindoria, Lohit
Munoz, Javier
Reagan, Patrick
Goy, Andre
Miklos, David
Zheng, Dan
Fang, Xiang
Shen, Rhine
Siddiqi, Rubina
Kloos, Ioana
Kersten, Marie Jose
Wang, Michael
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 113 - 114
[4] Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
van Meerten, Tom
Kersten, M. J.
Lacoboni, Gloria
Hess, Georg
Mutsaers, Pim
Garcia-Sancho, Alejandro Martin
Goy, Andre
Gine, Eva
Hill, Brian T.
Weng, Wen-Kai
Dreyling, Martin
Reagan, Patrick M.
Patel, Krish
Galal, Ahmed
Herbaux, Charles
Sanderson, Robin
Zheng, Dan
Kanska, Justyna
Zhang, Wangshu
Khalid, Rita Damico
Kloos, Loana
Wang, Michael
BLOOD, 2024, 144 : 748 - 750
[5] Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/ Refractory Mantle Cell Lymphoma (R/R MCL)
Munoz, Javier
Reagan, Patrick M.
Goy, Andre H.
Miklos, David B.
Zheng, Dan
Fang, Xiang
Shen, Rhine R.
Siddiqi, Rubina
Kloos, Ioana
Kersten, Marie Jose
Wang, Michael
BLOOD, 2022, 140 : 9320 - 9322
[6] A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
Hess, Georg
Dreyling, Martin
Oberic, Lucie
Gine, Eva
Zinzani, Pier Luigi
Linton, Kim M.
Vilmar, Adam
Jerkeman, Mats
Chen, Jenny M. H.
Ohler, Anke
Stilgenbauer, Stephan
Thieblemont, Catherine
Lambert, Jonathan
Zilioli, Vittorio Ruggero
Sancho, Juan-Manuel
Jimenez-Ubieto, Ana
Fischer, Luca
Eyre, Toby A.
Keeping, Sam
Park, Julie E.
Wu, James J.
Siddiqi, Rubina
Reitan, John
Castaigne, Gab
Salles, Gilles
BLOOD, 2022, 140 : 10296 - 10299
[7] Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
Kambhampati, Swetha
Ahmed, Nausheen
Hamadani, Mehdi
Grover, Natalie Sophia
Shadman, Mazyar
Locke, Frederick L.
Gerson, James M.
Frank, Matthew Joshua
Budde, Lihua Elizabeth
Wang, Michael
Hu, Zhen-Huan
Nunes, Ana
Dalton, David
Kloos, Ioana
Lee, Daniel
Xu, Hairong
Pasquini, Marcelo C.
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Real-World Outcomes of Brexucabtagene Autoleucel ( Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics
Kambhampati, Swetha
Ahmed, Nausheen
Hamadani, Mehdi
Kim, Soyoung
Hemmer, Michael T.
Grover, Natalie S.
Shadman, Mazyar
Beitinjaneh, Amer
Budde, L. Elizabeth
Gerson, James
Jacobson, Caron A.
Locke, Frederick L.
Nasta, Dwivedy S.
Wang, Michael L.
Weng, Wen-Kai
Yan, Jiali
Nunes, Ana
Dalton, David
Wu, James J.
Abdeldaim, Amina
Hu, Zhen-Huan
Pasquini, Marcelo
Herrera, Alex F.
BLOOD, 2023, 142
[9] Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3
Oluwole, Olalekan O.
Ghobadi, Armin
Cassaday, Ryan Daniel
Park, Jae H.
Houot, Roch
Logan, Aaron
Boissel, Nicolas
Leguay, Thibaut
Bishop, Michael Russell
Topp, Max S.
O'Dwyer, Kristen M.
Baer, Maria R.
Schiller, Gary J.
Abedi, Mehrdad
Minnema, Monique C.
Stiff, Patrick J.
Zhou, Lang
Siddiqi, Rubina
Khalid, Rita Damico
Shah, Bijal D.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Matching-Adjusted Indirect Comparison (MAIC) of Brexucabtagene Autoleucel (Brexu-cel) and Pirtobrutinib in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)
Chen, Jenny M. H.
Zhang, Ina
Wu, James J.
Wade, Sally W.
Nunes, Ana
Peng, Weimin
Snider, Julia T.
Maciel, Dylan
Chan, Keith
Keeping, Sam
Shah, Bijal D.
BLOOD, 2023, 142

← 1 2 3 4 5 →